目的 探讨元胡止痛滴丸联合苯甲酸利扎曲普坦片治疗偏头痛的临床疗效。方法 纳入2022年1月—2023年12月在新乡医学院第一附属医院就诊的160偏头痛患者，按照随机数字表法分为对照组和治疗组，每组各80例。对照组患者口服苯甲酸利扎曲普坦片，10 mg/次，2次/d；治疗组在对照组基础上口服元胡止痛滴丸，20丸/次，3次/d。两组患者均治疗1个月。观察两组患者临床疗效，比较治疗前后两组患者VAS评分和VAS评分降低至少50%所需时间，及血浆黏度（PV）、全血低切黏度（LSWBV）、全血高切黏度（HSWBV）、纤维蛋白原（FIB）、5-羟色胺（5-HT）、一氧化氮（NO）、多巴胺（DA）、降钙素基因相关肽（CGRP）、白细胞介素-1β（IL-1β）和肿瘤坏死因子-α（TNF-α）水平。结果 治疗后，对照组总有效率为78.75%，治疗组总有效率为91.25%，两组比较差异具有统计学意义（P＜0.05）。治疗后，两组VAS评分均显著降低（P＜0.05），且治疗组VAS评分显著低于对照组（P＜0.05）。治疗后，治疗组VAS评分降低至少50%所需时间显著低于对照组（P＜0.05）。治疗后，两组PV、LSWBV、HSWBV、FIB、NO、CGRP、DA、IL-1β和TNF-α水平均显著降低，而5-HT水平均显著升高（P＜0.05），且治疗组这些指标水平均显著好于对照组（P＜0.05）。结论 元胡止痛滴丸联合利扎曲普坦治疗偏头痛临床疗效显著，且安全性高，能快速缓解患者头痛症状，可能与改善血液黏度、神经递质及炎症因子的表达水平等有关。

Objective To investigate the clinical efficacy of Yuanhu Zhitong Pills combined with rizatriptan in treatment of migraine. Methods Patients (160 cases) with migraine in the First Affiliated Hospital of Xinxiang Medical University from January 2022 to December 2023 were divided into control and treatment group according to the random number table method, and each group had 80 cases. Patients in the control group were po administered with Rizatriptan Monobenzoate Tablets, 10 mg/time, twice daily. Patients in the treatment group were po administered with Yuanhu Zhitong Pills on the basis of the control group, 20 pills/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical evaluations were evaluated, the VAS scores and the time of VAS score decreased more than 50%, and the levels of PV, LSWBV, HSWBV, FIB, 5-HT, NO, CGRP, DA, IL-1β, and TNF-α in two groups before and after treatment were compared. Results After treatment, the total effective rate in the control group was 78.75%, the total effective rate in the treatment group was 91.25%, and the difference between the two groups was statistically significant (P < 0.05). After treatment, VAS scores in two groups were significantly reduced (P < 0.05), and VAS scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the time required for the VAS score to decrease by at least 50% in the treatment group was significantly lower than that in the control group (P < 0.05). After treatment, the levels of PV, LSWBV, HSWBV, FIB, NO, CGRP, DA, IL-1β, and TNF-α were significantly decreased in two groups, while the levels of 5-HT were significantly increased (P < 0.05), and the levels of these indicators in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Yuanhu Zhitong Pills combined with rizatriptan benzoate have significant clinical efficacy and high safety in the treatment of migraine. It can quickly relieve headache symptoms in patients, which may be related to improving blood viscosity, expression levels of neurotransmitters and inflammatory factors.

R971

河南省医学科技攻关计划项目（LHGJ20200488）